The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s meningococcal vaccines market report forecasts the meningococcal vaccines market size to grow to $5.09 Billion by 2027, with a CAGR (compound annual growth rate) of more than 9%.

Learn More On The Meningococcal Vaccines Market Report 2023 – https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Vaccines Market Size Forecast
The global meningococcal vaccines market is expected to grow from $3.21 billion in 2022 to $3.53 billion in 2023 at a compound annual growth rate (CAGR) of 10%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The meningococcal vaccines market size is expected to grow to $5.09 billion in 2027 at a CAGR of 9.6%.

North America held the largest meningococcal vaccines market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Meningococcal Vaccines Market Driver ­– Increase In Healthcare Spending
For instance, in May 2022, according to an article published by the American Medical Association, a US-based professional association and lobbying group of physicians and medical students, healthcare spending in the United States had risen by 9.7% to $4.1 trillion, or $12,530 per person. This pace of growth is significantly higher than 2019’s (4.3%). Therefore, an increase in healthcare spending is driving the growth of the meningococcal vaccine market.

Request for A Sample Of The Global Meningococcal Vaccines Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

Key Meningococcal Vaccines Market Trend – Product Innovation
Major players operating in the meningococcal vaccines market are creating innovative new items using cutting-edge technology to maintain their position in the meningococcal vaccines market. For instance, in April 2020, Sanofi Pasteur Inc., a France-based life-protecting vaccines company, received Food and Drug Administration (FDA) approval for the usage of menquadfi by those who are at least 2 years old. Menquadfi helps to prevent the spread of invasive meningococcal illnesses (including meningitis) caused by the bacteria N meningitides serogroups A, C, W, and Y. The initial and single quadrivalent meningococcal strains are called MenQuadfi vaccinations. It employs tetanus toxoid as a protein carrier and is accessible in a ready-to-use liquid format, eliminating the need for healthcare personnel to reconstitute the vaccine.

Meningococcal Vaccines Market Segment
1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine
2) By Serotype: Men Acwy, Men B/Bc, Men C
3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults
4) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Channels
5) By End user: Hospitals, Research, Academic Institutes

Meningococcal Vaccines Market Major Players and Strategies
Major players in the meningococcal vaccines market are Pfizer Inc., Novartis AG, Sanofi S.A., Serum Institute of India Pvt. Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Incepta Pharmaceuticals Ltd., Bio-Med Limited, Walvax Biotechnology Co., Ltd., Bio-Manguinhos, Hualan Biological Engineering Inc., JN-International Medical Corporation, Johnson & Johnson, AstraZeneca plc, and Bavarian Nordic A/S.

In August 2022, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology company, acquired Affinivax Inc. for $3.3 billion. The acquisition of Affinivax is consistent with GSK’s aim of establishing a robust portfolio of specialty medicines and vaccines. Affinivax, Inc., is a US-based next-generation vaccine technology company operating in the meningococcal vaccines market.

The Meningococcal Vaccines Global Market Report 2023 covers regional data on meningococcal vaccines market size, meningococcal vaccines market trends and drivers, opportunities, strategies, and meningococcal vaccines market competitor analysis. The countries covered in the meningococcal vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Meningococcal vaccinations are vaccines that protect against meningococcal meningitis, an infection with the bacterium Neisseria meningitides that leads to inflammation of the tissues that surround the brain and spinal cord.

View More Reports Related To The Meningococcal Vaccines Market –
Pediatric Vaccine Global Market Report 2023
Companion Animal Veterinary Vaccines Global Market Report 2023
DTP Vaccines Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: